- Market Capitalization, $K 587,910
- Shares Outstanding, K 296,924
- Annual Sales, $ 17,980 K
- Annual Income, $ -72,440 K
- 60-Month Beta 2.15
- Price/Sales 33.19
- Price/Cash Flow N/A
- Price/Book 2.12
|Period||Period Low||Period High||Performance|
| || |
-0.1900 (-8.52%)since 11/02/22
| || |
-0.2700 (-11.69%)since 09/02/22
| || |
-1.6700 (-45.01%)since 12/02/21
Bionano Genomics, Inc. (BNGO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could...
Biotech company Bionano Genomics (BNGO) has beaten analysts’ top-line estimate in the third quarter. However, its cash and cash equivalents balance has declined year-over-year. Therefore, is it a buy...
These low-priced equities could explode higher soon.
Wall Street analysts expect Biotech stock Bionano Genomics (BNGO) to grow more than 160% in the near term. However, the stock’s fundamentals appear bleak, and the stock has lost more than 20% in 2022....
BNGO earnings call for the period ending September 30, 2022.
Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of 8.33% and 7.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...
Select analysts and pundits foresee game-changing upside from this fast-paced trio.
Bionano's stock price movements have little to do with its successes.
On an up day for Wall Street, the genome-mapping company may have benefited from a short squeeze.
|Bionano Genomics Inc|
|Gx Genomics & Biotechnology ETF|
|SPDR Kensho & New Economies Composite ETF|
|Principal Healthcare Innovators Index|
|Micro-Cap Ishares ETF|
|Russell 2000 Value Ishares ETF|
|3rd Resistance Point||2.2978|
|2nd Resistance Point||2.2237|
|1st Resistance Point||2.1018|
|1st Support Level||1.9058|
|2nd Support Level||1.8317|
|3rd Support Level||1.7098|